CN103656001A - Compound medicine for treating osteoproliferation - Google Patents
Compound medicine for treating osteoproliferation Download PDFInfo
- Publication number
- CN103656001A CN103656001A CN201310698948.4A CN201310698948A CN103656001A CN 103656001 A CN103656001 A CN 103656001A CN 201310698948 A CN201310698948 A CN 201310698948A CN 103656001 A CN103656001 A CN 103656001A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- compound medicine
- resina
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a compound medicine for treating osteoproliferation. The compound medicine for treating the osteoproliferation comprises the components in parts by weight according to a proportional range as follows: 40-60 parts of mastic, 40-60 parts of myrrh, 25-35 parts of rhizoma corydalis, 25-35 parts of radix clematidis, 20-30 parts of rhizoma arisaematis, 10-20 parts of ferula asafoetida, 10-20 parts of gamboge, 10-20 parts of radix aconiti, 3-8 parts of deer horns, 3-8 parts of tortoise plastrons, 3-8 parts of turtle shells, 3-8 parts of beef tendons, 3-8 parts of rubus cochinchinensis, 5-10 parts of Japanese cayratia herbs, 15-30 parts of ground ivy herbs and 15-30 parts of fructus psoraleae. According to the compound medicine, sixteen kinds of traditional Chinese medicines are selected and compatible with one another, monarchs and ministers join in a common effort and assistants and guides assist together in a formula, and all the medicines are used together, so that the compound medicine has functions of clearing channels, activating collaterals, expelling wind and alleviating pain, is applied to treatment of the osteoproliferation, is short in treatment course, good in curative effect, high in cure rate, convenient to apply and free from toxic and side effects and is the ideal natural compound medicine for treating the osteoproliferation.
Description
Technical field
The present invention relates to a kind of orthopaedics Chinese medicine, particularly a kind of compound medicine for the treatment of hyperosteogeny.
Background technology
Hyperosteogeny claims again hypertrophy disease, hypertrophy or degenerative osteoarthritis.Be apt to occur in cervical vertebra, lumbar vertebra, hip, knee joint, root bone etc. and locate, can single-shot or multiple.For common ailment of middle-aged and old, frequently-occurring disease.Due to the paathogenic factor of primary disease has the loss of deficiency of the liver and kindey, essence and blood more or wind-cold damp pathogen is taken advantage of a weak point, the resistance of QI and blood numbness, muscles and bones mistake support.Because of the local excitation affected part tendon of the sclerotin of hypertrophy nervous, peripheral nerve pressurized, therefore symptoms such as affected part pain, function limitations.X-ray is penetrated sheet and is checked that osteoarthrosis is hypertrophy or degenerative change.Treatment primary disease adopts massage to come the methods such as relief of symptoms or physical therapy, also useful medicine person more at present.But because the misery causing to patient is too many, and effect is also undesirable, massage and also to lose time, also have some medicine for external use, but mostly have that effect is undesirable, also high, the problem such as the course for the treatment of is long, produce effects slowly of delay treatment, cost.The Chinese patent literature of Chinese patent CN101874892A provides a kind of hyperosteogeny that is used for the treatment of, the health care external medicinal liquid of lumbar vertebra protrusion, by Radix Clematidis, Pollen Typhae, Folium Artemisiae Argyi, the Radix Aucklandiae, Cortex erythrinae, Squama Manis, Scorpio, joy clam, Herba speranskiae tuberculatae, Ramulus Cinnamomi, Rhizoma Polygoni Cuspidati, Flos Carthami, Radix Aconiti, Radix Aconiti Kusnezoffii, Eupolyphaga Seu Steleophaga, Herba Asari, Pericarpium Zanthoxyli, Semen Ricini, the Radix Angelicae Dahuricae, Flos Caryophylli, Squama Manis, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Radix Angelicae Sinensis, Fructus Perillae, Radix Cyathulae, CHUANSHAO, Radix Paeoniae Rubra, Rhizoma Corydalis, Radix Notoginseng, the Rhizoma Pinelliae, Semen Strychni, Radix Salviae Miltiorrhizae, Fructus Chaenomelis, Radix Saposhnikoviae, Rhizoma Zingiberis, Cortex Cinnamomi, Radix Aconiti Lateralis Preparata, Fructus Evodiae, Rhizoma Alpiniae Officinarum, Fructus Piperis, anistree mattress is fragrant, Sanguis Draxonis, Rhizoma Arisaematis, Herba Ephedrae, Borneolum Syntheticum, road is fragrant, Lignum Pini Nodi, Camphora, raw mountain quarrel, the 51 taste Chinese medicines such as WAGNWEIZI are made.The Chinese patent literature of Chinese patent CN100425265C provides a kind of a kind of Chinese medicine composition that can effectively treat hyperosteogeny that the invention provides, and this medicine is to be made by crude drug such as Radix Angelicae Sinensis, Rhizoma Et Radix Notopterygii, punt-pole basis, Radix Aconiti, Radix Aconiti Lateralis Preparata, CHUANSHAO, Radix Paeoniae Rubra, Flos Carthami, Pheretima, Sanguis Draxonis, first Pu, Medulla Junci, Herba Asari, Ramulus Cinnamomi, Radix Salviae Miltiorrhizae, Radix Saposhnikoviae, Semen Raphani, Semen Sinapis Albae, Radix Clematidis, Olibanum, Myrrha, stockaded village's perfume, Borneolum Syntheticums.Prior art exist easily cause untoward reaction, be difficult for accurate dosage, the formula dosage form shortcoming such as science not, and mainly with relieving the pain as principle for the treatment of, cure rate is low, can only take stopgap measures to effect a permanent cure, and all can not fundamentally cure curing hyperosteogeny disease.
Summary of the invention
The technical problem to be solved in the present invention is the above-mentioned defect that how to overcome prior art, and auxiliary compound medicine for a kind of synthetism is provided.
For solving the problems of the technologies described above, the compound medicine of this treatment hyperosteogeny by following component according to shown in weight ratio scope prepare, 40～60 parts of Olibanums, 40～60 parts of Myrrhas, 25～35 parts of Rhizoma Corydalis, 25～35 parts of Radix Clematidis, 20～30 parts of Rhizoma Arisaematiss, 10～20 parts of Resina Ferulaes, 10～20 parts of Resina garciniaes, 10～20 parts of Radix Aconitis, 3～8 parts, Cornu Cervi, 3～8 parts of Carapax et Plastrum Testudiniss, 3～8 parts of Carapax Trionycis, 3～8 parts of Ungula Bovis seu Bubali muscle, 3～8 parts of Radix seu FoliumRubi Cochinchinensis, 5～10 parts of Herba Ipomoeae Cairicaes, 15～30 parts of Radix seu Folium Gaultheriae Forrestiis, 15～30 parts of Fructus Psoraleaes.
As optimum ratio scope, described compound medicine by following component according to shown in weight ratio scope prepare, 49～51 parts of Olibanums, 49～51 parts of Myrrhas, 29～31 parts of Rhizoma Corydalis, 29～31 parts of Radix Clematidis, 29～31 parts of Rhizoma Arisaematiss, 14～16 parts of Resina Ferulaes, 14～16 parts of Resina garciniaes, 14～16 parts of Radix Aconitis, 5～7 parts, Cornu Cervi, 5～7 parts of Carapax et Plastrum Testudiniss, 5～7 parts of Carapax Trionycis, 5～7 parts of Ungula Bovis seu Bubali muscle, 5～7 parts of Radix seu FoliumRubi Cochinchinensis, 7～9 parts of Herba Ipomoeae Cairicaes, 23～25 parts of Radix seu Folium Gaultheriae Forrestiis, 23～25 parts of Fructus Psoraleaes.
As optimum ratio, described compound medicine by following component according to shown in weight ratio prepare, 60 parts of Olibanums, 40 parts of Myrrhas, 35 parts of Rhizoma Corydalis, Radix Clematidis 25 30 parts, part, day south, 10 parts of Resina Ferulaes, 20 parts of Resina garciniaes, 10 parts of Radix Aconitis, 8 parts, Cornu Cervi, 3 parts of Carapax et Plastrum Testudiniss, 8 parts of Carapax Trionycis, 3 parts of Ungula Bovis seu Bubali muscle, 8 parts of Radix seu FoliumRubi Cochinchinensis, 5 parts of Herba Ipomoeae Cairicaes, 30 parts of Radix seu Folium Gaultheriae Forrestiis, 15 parts of Fructus Psoraleaes.
As optimum ratio, described compound medicine by following component according to shown in weight ratio prepare, 40 parts of Olibanums, 60 parts of Myrrhas, 25 parts of Rhizoma Corydalis, 35 parts of Radix Clematidis, 20 parts of Rhizoma Arisaematiss, 20 parts of Resina Ferulaes, 10 parts of Resina garciniaes, 20 parts of Radix Aconitis, 3 parts, Cornu Cervi, 8 parts of Carapax et Plastrum Testudiniss, 3 parts of Carapax Trionycis, 8 parts of Ungula Bovis seu Bubali muscle, 3 parts of Radix seu FoliumRubi Cochinchinensis, 10 parts of Herba Ipomoeae Cairicaes, 15 parts of Radix seu Folium Gaultheriae Forrestiis, 30 parts of Fructus Psoraleaes.
As further optimum ratio, described compound medicine by following component according to shown in weight ratio prepare, 51 parts of Olibanums, 49 parts of Myrrhas, 31 parts of Rhizoma Corydalis, 29 parts of Radix Clematidis, 31 parts of Rhizoma Arisaematiss, 14 parts of Resina Ferulaes, 16 parts of Resina garciniaes, 14 parts of Radix Aconitis, 7 parts, Cornu Cervi, 5 parts of Carapax et Plastrum Testudiniss, 7 parts of Carapax Trionycis, 5 parts of Ungula Bovis seu Bubali muscle, 7 parts of Radix seu FoliumRubi Cochinchinensis, 7 parts of Herba Ipomoeae Cairicaes, 25 parts of Radix seu Folium Gaultheriae Forrestiis, 23 parts of Fructus Psoraleaes.
As further optimum ratio, described compound medicine by following component according to shown in weight ratio prepare, 49 parts of Olibanums, 51 parts of Myrrhas, 29 parts of Rhizoma Corydalis, 31 parts of Radix Clematidis, 29 parts of Rhizoma Arisaematiss, 16 parts of Resina Ferulaes, 146 parts of Resina garciniaes, 16 parts of Radix Aconitis, 5 parts, Cornu Cervi, 7 parts of Carapax et Plastrum Testudiniss, 5 parts of Carapax Trionycis, 7 parts of Ungula Bovis seu Bubali muscle, 5 parts of Radix seu FoliumRubi Cochinchinensis, 9 parts of Herba Ipomoeae Cairicaes, 23 parts of Radix seu Folium Gaultheriae Forrestiis, 25 parts of Fructus Psoraleaes.
As best proportioning, described compound medicine by following component according to shown in weight ratio prepare, 50 parts of Olibanums, 50 parts of Myrrhas, 30 parts of Rhizoma Corydalis, 30 parts of Radix Clematidis, 30 parts of Rhizoma Arisaematiss, 15 parts of Resina Ferulaes, 15 parts of Resina garciniaes, 15 parts of Radix Aconitis, 6 parts, Cornu Cervi, 6 parts of Carapax et Plastrum Testudiniss, 6 parts of Carapax Trionycis, 6 parts of Ungula Bovis seu Bubali muscle, 6 parts of Radix seu FoliumRubi Cochinchinensis, 8 parts of Herba Ipomoeae Cairicaes, 24 parts of Radix seu Folium Gaultheriae Forrestiis, 24 parts of Fructus Psoraleaes.
Pharmacology analysis
Olibanum: acrid in the mouth, hardship, warm in nature; GUIXIN, liver, spleen channel; Regulating qi and activating blood, fixed logical, chase after malicious effect.
Myrrha: bitter in the mouth, pungent, property is flat; Return liver, spleen, the heart, kidney channel; Logical stagnant blood, beats and flutters damage pain, promoting blood circulation and stopping pain, detumescence and promoting granulation.
Rhizoma Corydalis: bitter in the mouth, pungent, warm in nature; Return liver, the heart, stomach warp; Benefaction is wandered away, and can rise to fall to have promoting blood circulation to remove blood stasis, the effect of promoting the circulation of QI to relieve pain.
Radix Clematidis: bitter in the mouth, temperature, nontoxic; Return urinary bladder channel; Pungent loose being apt to away, tonneau warm in nature 12 warps that can pass through, can drive at the wind of table and can change again inner wetting, and stimulate the menstrual flow and reach network, can lead the key medicine that can declare as gout.
Rhizoma Arisaematis: acrid in the mouth, micro-hardship, warm in nature, toxic; Return lung meridian; Dampness, dredging collateral, opens and steals, pain relieving endogenous wind stopping.
Resina Ferulae: acrid in the mouth, property are flat, nontoxic; Return kidney, stomach warp; Ferulic acid volatilization wet goods can be benumbed nerve centre, therefore there is analgesia spasmolytic sedation, the effect that also has vitamin antagonist E to lack, therefore can soften the sclerotin of hypertrophy.
Resina garciniae: sour in the mouth, puckery, cool in nature, poisonous; Return large intestine, small intestinal, spleen channel; Detumescence, removing toxic substances, hemostasis, parasite killing.Control swollen ulcer drug, stubborn dermatitis malignant boil, bleeding due to trauma, ulcerative gingivitis decayed tooth, burn.
Radix Aconiti: acrid in the mouth, hardship, hot in nature; GUIXIN, liver,kidney,spleen warp; Expelling wind and removing dampness, antalgic, has a pain for anemofrigid-damp arthralgia, arthralgia, trusted subordinate's cold type of pain, colic of cold type.Be used for the treatment of the diseases such as anemofrigid-damp arthralgia, arthralgia.
Cornu Cervi: salty in the mouth, warm in nature; Return liver, kidney channel; Promoting the circulation of blood, detumescence, kidney tonifying, controls sore swollen toxin, and blood stasis is had a pain, asthenia internal injury, lumbar vertebrae pain.
Carapax et Plastrum Testudinis: salty in the mouth, sweet, property is flat; GUIXIN, spleen, liver three warps; YIN nourishing, YANG hyperactivity suppressing, the kidney invigorating, strong bone, controls deficiency of kidney yin, and hectic fever due to YIN-deficiency consumptive fever is spitted blood, epistaxis, chronic cough, seminal emission, metrorrhagia, leukorrhagia, lumbago, the atrophic debility of bones, stirring of wind due to deficiency of YIN.
Carapax Trionycis: salty in the mouth, cold in nature; Return liver, kidney channel; Nourishing kidney YANG hyperactivity suppressing, hard masses softening and resolving, controls hard under hectic fever due to YIN-deficiency consumptive fever, malaria with splenomegaly, the side of body, lumbago, the diseases such as amenorrhea lump in the abdomen.
Ungula Bovis seu Bubali muscle: sweet in the mouth, warm in nature; Enter spleen, kidney channel; Have QI invigorating tonify deficiency, the effect during warming middle-JIAO is warm, mends scleroprotein, collagen fiber.
Radix seu FoliumRubi Cochinchinensis: bitter in the mouth, puckery, cold nature; Heat clearing and blood cooling, eliminating stasis to stop pain, inducing diuresis to remove edema.
Herba Ipomoeae Cairicae: sour in the mouth, hardship, cold in nature, nontoxic; GUIXIN, liver, stomach warp; Heat-clearing and toxic substances removing, promoting blood circulation to remove blood stasis, diuresis.For laryngopharynx swelling and pain, furuncle and phyma, carbuncle, furuncle, dysentery, hematuria, nebulousurine, traumatic injury, venom.
Radix seu Folium Gaultheriae Forrestii: bitter in the mouth, pungent, warm in nature; Dispel the wind, dehumidifying, dispelling the wind and dampness pathogens paralysis, chilblain.
Fructus Psoraleae: acrid in the mouth, hardship, warm in nature; Return kidney, pericardium, spleen, stomach, lung meridian; Bone growth promoting Bu Shen Zhuang yang-energy.
The compound medicine of this treatment hyperosteogeny is external application paste, its preparation method is, first according to above-mentioned weight portion, get each component, each component is mixed or be ground into fine powder, cross 100 mesh sieves, make medicated powder, by Oleum sesami and Colophonium furnishing pasty state ointment for this medicated powder, be applied in two-layer nonwoven, spread on affected part outward, a course for the treatment of on the 3rd, force on, change dressings every other day cream once per course for the treatment of 2.The present invention's total mechanism of action used is: the mechanism of action of application traditional Chinese medical science inner disease outer treat, hereby from meridians conduction, skin penetrate, mucosa absorption, to realize therapeutical effect.
It is monarch drug that a kind of synthetism of the present invention be take Olibanum, Myrrha, Cornu Cervi, Carapax et Plastrum Testudinis, Carapax Trionycis, Ungula Bovis seu Bubali muscle, Radix seu FoliumRubi Cochinchinensis, Herba Ipomoeae Cairicae with auxiliary compound medicine, take Rhizoma Corydalis, Radix Clematidis, Rhizoma Arisaematis, Resina Ferulae, Resina garciniae, Radix Aconiti is ministerial drug, and Radix seu Folium Gaultheriae Forrestii, Fructus Psoraleae are that adjuvant is formulated; In side, the monarch and his subjects pull together, help and make auxiliaryly altogether, and all medicines share, and have the effect of dredge the meridian passage, wind-expelling pain-stopping.Can be in order to treat the diseases such as hyperosteogeny, rheumatic arthritis, rheumatoid arthritis, traumatic injury, be directed to especially hyperosteogeny, its short treating period, good effect, cure rate be high, stick conveniently, have no side effect, and is a kind of natural compound medicine of desirable treatment hyperosteogeny.
The specific embodiment
Embodiment 1: the preparation method of the compound medicine external application paste of this treatment hyperosteogeny is, first according to 60 parts of Olibanums, 40 parts of Myrrhas, 35 parts of Rhizoma Corydalis, 25 parts of Radix Clematidis, 30 parts, it south, 10 parts of Resina Ferulaes, 20 parts of Resina garciniaes, 10 parts of Radix Aconitis, 8 parts, Cornu Cervi, 3 parts of Carapax et Plastrum Testudiniss, 8 parts of Carapax Trionycis, 3 parts of Ungula Bovis seu Bubali muscle, 8 parts of Radix seu FoliumRubi Cochinchinensis, 5 parts of Herba Ipomoeae Cairicaes, 30 parts of Radix seu Folium Gaultheriae Forrestiis, the weight ratio that Fructus Psoraleae is 15 parts is got each component, each component is mixed or be ground into fine powder, cross 100 mesh sieves, make medicated powder, by Oleum sesami and Colophonium furnishing pasty state ointment for this medicated powder, be applied in two-layer nonwoven, obtain the compound medicine external application paste A of this treatment hyperosteogeny.
Embodiment 2: the preparation method of the compound medicine external application paste of this treatment hyperosteogeny is, first according to 40 parts of Olibanums, 60 parts of Myrrhas, 25 parts of Rhizoma Corydalis, 35 parts of Radix Clematidis, 20 parts of Rhizoma Arisaematiss, 20 parts of Resina Ferulaes, 10 parts of Resina garciniaes, 20 parts of Radix Aconitis, 3 parts, Cornu Cervi, 8 parts of Carapax et Plastrum Testudiniss, 3 parts of Carapax Trionycis, 8 parts of Ungula Bovis seu Bubali muscle, 3 parts of Radix seu FoliumRubi Cochinchinensis, 10 parts of Herba Ipomoeae Cairicaes, 15 parts of Radix seu Folium Gaultheriae Forrestiis, the weight ratio that Fructus Psoraleae is 30 parts is got each component, each component is mixed or be ground into fine powder, cross 100 mesh sieves, make medicated powder, by Oleum sesami and Colophonium furnishing pasty state ointment for this medicated powder, be applied in two-layer nonwoven, obtain the compound medicine external application paste B of this treatment hyperosteogeny.
Embodiment 3: the preparation method of the compound medicine external application paste of this treatment hyperosteogeny is, first according to 51 parts of Olibanums, 49 parts of Myrrhas, 31 parts of Rhizoma Corydalis, 29 parts of Radix Clematidis, 31 parts of Rhizoma Arisaematiss, 14 parts of Resina Ferulaes, 16 parts of Resina garciniaes, 14 parts of Radix Aconitis, 7 parts, Cornu Cervi, 5 parts of Carapax et Plastrum Testudiniss, 7 parts of Carapax Trionycis, 5 parts of Ungula Bovis seu Bubali muscle, 7 parts of Radix seu FoliumRubi Cochinchinensis, 7 parts of Herba Ipomoeae Cairicaes, 25 parts of Radix seu Folium Gaultheriae Forrestiis, the weight ratio that Fructus Psoraleae is 23 parts is got each component, each component is mixed or be ground into fine powder, cross 100 mesh sieves, make medicated powder, by Oleum sesami and Colophonium furnishing pasty state ointment for this medicated powder, be applied in two-layer nonwoven, obtain the compound medicine external application paste C of this treatment hyperosteogeny.
Embodiment 4: the preparation method of the compound medicine external application paste of this treatment hyperosteogeny is, first according to 49 parts of Olibanums, 51 parts of Myrrhas, 29 parts of Rhizoma Corydalis, 31 parts of Radix Clematidis, 29 parts of Rhizoma Arisaematiss, 16 parts of Resina Ferulaes, 146 parts of Resina garciniaes, 16 parts of Radix Aconitis, 5 parts, Cornu Cervi, 7 parts of Carapax et Plastrum Testudiniss, 5 parts of Carapax Trionycis, 7 parts of Ungula Bovis seu Bubali muscle, 5 parts of Radix seu FoliumRubi Cochinchinensis, 9 parts of Herba Ipomoeae Cairicaes, 23 parts of Radix seu Folium Gaultheriae Forrestiis, the weight ratio that Fructus Psoraleae is 25 parts is got each component, each component is mixed or be ground into fine powder, cross 100 mesh sieves, make medicated powder, by Oleum sesami and Colophonium furnishing pasty state ointment for this medicated powder, be applied in two-layer nonwoven, obtain the compound medicine external application paste D of this treatment hyperosteogeny.
Embodiment 5: the preparation method of the compound medicine external application paste of this treatment hyperosteogeny is, first according to 50 parts of Olibanums, 50 parts of Myrrhas, 30 parts of Rhizoma Corydalis, 30 parts of Radix Clematidis, 30 parts of Rhizoma Arisaematiss, 15 parts of Resina Ferulaes, 15 parts of Resina garciniaes, 15 parts of Radix Aconitis, 6 parts, Cornu Cervi, 6 parts of Carapax et Plastrum Testudiniss, 6 parts of Carapax Trionycis, 6 parts of Ungula Bovis seu Bubali muscle, 6 parts of Radix seu FoliumRubi Cochinchinensis, 8 parts of Herba Ipomoeae Cairicaes, 24 parts of Radix seu Folium Gaultheriae Forrestiis, the weight ratio that Fructus Psoraleae is 24 parts is got each component, each component is mixed or be ground into fine powder, cross 100 mesh sieves, make medicated powder, by Oleum sesami and Colophonium furnishing pasty state ointment for this medicated powder, be applied in two-layer nonwoven, obtain the compound medicine external application paste E of this treatment hyperosteogeny.
In above-described embodiment, embodiment 5 is most preferred embodiment of the present invention.
Clinical data
Year January in April, 2012 to 2013 is totally 50 routine hyperosteogeny patients or with pain, applies 40 years old mean age of 20～60 years old age of the present invention, the course of disease one to ten year, and sex male is more than women.In sufferer 50 examples, effective 49 examples, invalid 1 example, total effective rate 98%.Effect is better than matched group, and during treatment, except two examples are to non-woven fabrics allergy, warp is stopped using two days without allergic phenomena, without other untoward reaction.
Model case (all selecting from above-mentioned 150 routine patients)
Case 1: Europe, female, 57 years old, teacher.Rigidity of the neck, easy stiff neck, remaining closely half a year, right arm was numb year in year out.Have sense of heaviness, left hand held object is unable, unable when head is changed one's position.Thready and stringy pulse, white and thin fur, cervical vertebra film making shows: C5,6,7 physiologic radians straighten, gap slightly narrows down, and C5, C6 trailing edge are shown in lip sample hyperosteogeny, traction therapeutic once, poor effect.Advise the compound medicine external application paste E that sticks this treatment hyperosteogeny making with embodiment 5, with rear first quarter moon stiffness of the neck, be clearly better, arm picotement alleviates, and is used in conjunction one month, and all symptoms all disappear, and follows up a case by regular visits to not recurrence in a year.
Case 2: Xiao, female, 40 years old, Choreographer.More than double knee joint pain October, affect stride, once penetrate sheet inspection and be diagnosed as bilateral knee hyperosteogeny.Arthroncus, aggravation when year is met Changes in weather.Advise the compound medicine external application paste E that sticks this treatment hyperosteogeny making with embodiment 5 to treat two Zhou Zhouhou, subjective symptoms obviously alleviates, and while walking, stride phenomenon takes a turn for the better, and arthroncus also alleviates, and continues medication 20 days, and above-mentioned symptom disappears.Following up a case by regular visits to a year and a half does not recur.
Case 3: Chen, man, 30 years old, driver.More than lumbago half a year, by suffer from cold and impairment caused by overstrain after cause, its disease be take right side as acute, changing one's position, it is unfavorable to face upward mansion.Once Western medicine diagnose was lumbar muscle strain, lumbar vertebra 4,5 is slight hypertrophy, stomach discomfort after medicine, require external treatment, stick the compound medicine external application paste E of this treatment hyperosteogeny making with embodiment 5, five days low back alleviation of pain of medication are light, first quarter moon heals, and after half a year, recurs, and continues and within more than ten days, heals with the present invention.With not recurrence in anti-15 months.
Case 4: week certain, man, 50 years old, civil servant.Lumbago more than 1 year, with left side for very, to buttocks and thigh, move down gradually, through orthopaedics inspection, be diagnosed as hyperosteogeny, sciatica, night is because of cold type of pain impact sleep, advise with the compound medicine external application paste E more than ten that sticks this treatment hyperosteogeny making with embodiment 5 and paste, state of an illness recovery from illness, follows up a case by regular visits to not recurrence in 18 months.
Above-mentioned embodiment is intended to illustrate the present invention and can be professional and technical personnel in the field's realization or use; it will be apparent for those skilled in the art that above-mentioned embodiment is modified; therefore the present invention includes but be not limited to above-mentioned embodiment; any these claims or description of meeting described; meet and principle disclosed herein and novelty, the method for inventive features, technique, product, within all falling into protection scope of the present invention.
Claims (8)
1. a compound medicine for the treatment of hyperosteogeny, it is characterized in that: this compound medicine by following component according to shown in weight ratio scope prepare, 40～60 parts of Olibanums, 40～60 parts of Myrrhas, 25～35 parts of Rhizoma Corydalis, 25～35 parts of Radix Clematidis, 20～30 parts of Rhizoma Arisaematiss, 10～20 parts of Resina Ferulaes, 10～20 parts of Resina garciniaes, 10～20 parts of Radix Aconitis, 3～8 parts, Cornu Cervi, 3～8 parts of Carapax et Plastrum Testudiniss, 3～8 parts of Carapax Trionycis, 3～8 parts of Ungula Bovis seu Bubali muscle, 3～8 parts of Radix seu FoliumRubi Cochinchinensis, 5～10 parts of Herba Ipomoeae Cairicaes, 15～30 parts of Radix seu Folium Gaultheriae Forrestiis, 15～30 parts of Fructus Psoraleaes.
2. the compound medicine for the treatment of hyperosteogeny according to claim 1, it is characterized in that: described compound medicine by following component according to shown in weight ratio scope prepare, 49～51 parts of Olibanums, 49～51 parts of Myrrhas, 29～31 parts of Rhizoma Corydalis, 29～31 parts of Radix Clematidis, 29～31 parts of Rhizoma Arisaematiss, 14～16 parts of Resina Ferulaes, 14～16 parts of Resina garciniaes, 14～16 parts of Radix Aconitis, 5～7 parts, Cornu Cervi, 5～7 parts of Carapax et Plastrum Testudiniss, 5～7 parts of Carapax Trionycis, 5～7 parts of Ungula Bovis seu Bubali muscle, 5～7 parts of Radix seu FoliumRubi Cochinchinensis, 7～9 parts of Herba Ipomoeae Cairicaes, 23～25 parts of Radix seu Folium Gaultheriae Forrestiis, 23～25 parts of Fructus Psoraleaes.
3. the compound medicine for the treatment of hyperosteogeny according to claim 1, it is characterized in that: described compound medicine by following component according to shown in weight ratio prepare, 60 parts of Olibanums, 40 parts of Myrrhas, 35 parts of Rhizoma Corydalis, Radix Clematidis 25 30 parts, part, day south, 10 parts of Resina Ferulaes, 20 parts of Resina garciniaes, 10 parts of Radix Aconitis, 8 parts, Cornu Cervi, 3 parts of Carapax et Plastrum Testudiniss, 8 parts of Carapax Trionycis, 3 parts of Ungula Bovis seu Bubali muscle, 8 parts of Radix seu FoliumRubi Cochinchinensis, 5 parts of Herba Ipomoeae Cairicaes, 30 parts of Radix seu Folium Gaultheriae Forrestiis, 15 parts of Fructus Psoraleaes.
4. the compound medicine for the treatment of hyperosteogeny according to claim 1, it is characterized in that: described compound medicine by following component according to shown in weight ratio prepare, 40 parts of Olibanums, 60 parts of Myrrhas, 25 parts of Rhizoma Corydalis, 35 parts of Radix Clematidis, 20 parts of Rhizoma Arisaematiss, 20 parts of Resina Ferulaes, 10 parts of Resina garciniaes, 20 parts of Radix Aconitis, 3 parts, Cornu Cervi, 8 parts of Carapax et Plastrum Testudiniss, 3 parts of Carapax Trionycis, 8 parts of Ungula Bovis seu Bubali muscle, 3 parts of Radix seu FoliumRubi Cochinchinensis, 10 parts of Herba Ipomoeae Cairicaes, 15 parts of Radix seu Folium Gaultheriae Forrestiis, 30 parts of Fructus Psoraleaes.
5. the compound medicine for the treatment of hyperosteogeny according to claim 2, it is characterized in that: described compound medicine by following component according to shown in weight ratio prepare, 51 parts of Olibanums, 49 parts of Myrrhas, 31 parts of Rhizoma Corydalis, 29 parts of Radix Clematidis, 31 parts of Rhizoma Arisaematiss, 14 parts of Resina Ferulaes, 16 parts of Resina garciniaes, 14 parts of Radix Aconitis, 7 parts, Cornu Cervi, 5 parts of Carapax et Plastrum Testudiniss, 7 parts of Carapax Trionycis, 5 parts of Ungula Bovis seu Bubali muscle, 7 parts of Radix seu FoliumRubi Cochinchinensis, 7 parts of Herba Ipomoeae Cairicaes, 25 parts of Radix seu Folium Gaultheriae Forrestiis, 23 parts of Fructus Psoraleaes.
6. the compound medicine for the treatment of hyperosteogeny according to claim 2, it is characterized in that: described compound medicine by following component according to shown in weight ratio prepare, 49 parts of Olibanums, 51 parts of Myrrhas, 29 parts of Rhizoma Corydalis, 31 parts of Radix Clematidis, 29 parts of Rhizoma Arisaematiss, 16 parts of Resina Ferulaes, 146 parts of Resina garciniaes, 16 parts of Radix Aconitis, 5 parts, Cornu Cervi, 7 parts of Carapax et Plastrum Testudiniss, 5 parts of Carapax Trionycis, 7 parts of Ungula Bovis seu Bubali muscle, 5 parts of Radix seu FoliumRubi Cochinchinensis, 9 parts of Herba Ipomoeae Cairicaes, 23 parts of Radix seu Folium Gaultheriae Forrestiis, 25 parts of Fructus Psoraleaes.
7. the compound medicine for the treatment of hyperosteogeny according to claim 2, it is characterized in that: described compound medicine by following component according to shown in weight ratio prepare, 50 parts of Olibanums, 50 parts of Myrrhas, 30 parts of Rhizoma Corydalis, 30 parts of Radix Clematidis, 30 parts of Rhizoma Arisaematiss, 15 parts of Resina Ferulaes, 15 parts of Resina garciniaes, 15 parts of Radix Aconitis, 6 parts, Cornu Cervi, 6 parts of Carapax et Plastrum Testudiniss, 6 parts of Carapax Trionycis, 6 parts of Ungula Bovis seu Bubali muscle, 6 parts of Radix seu FoliumRubi Cochinchinensis, 8 parts of Herba Ipomoeae Cairicaes, 24 parts of Radix seu Folium Gaultheriae Forrestiis, 24 parts of Fructus Psoraleaes.
8. according to the compound medicine of the arbitrary described treatment hyperosteogeny of claim 1 to 7, it is characterized in that: described compound medicine is external application paste, its preparation method is, first according to the arbitrary described weight portion of claim 1 to 7, get each component, each component is mixed or be ground into fine powder, cross 100 mesh sieves, make medicated powder, by Oleum sesami and Colophonium furnishing pasty state ointment for this medicated powder, be applied in two-layer nonwoven, spread on affected part outward, a course for the treatment of on the 3rd, force on per course for the treatment of 2, change dressings every other day cream once, therapeutic effect is good.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310698948.4A CN103656001A (en) | 2013-12-18 | 2013-12-18 | Compound medicine for treating osteoproliferation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310698948.4A CN103656001A (en) | 2013-12-18 | 2013-12-18 | Compound medicine for treating osteoproliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103656001A true CN103656001A (en) | 2014-03-26 |
Family
ID=50295560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310698948.4A Pending CN103656001A (en) | 2013-12-18 | 2013-12-18 | Compound medicine for treating osteoproliferation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103656001A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288015A (en) * | 2015-12-03 | 2016-02-03 | 乔永平 | Combined crude drug ointment for treating hyperostosis |
| CN105327328A (en) * | 2015-12-12 | 2016-02-17 | 林炜 | Formula for treating osteoproliferation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101390988A (en) * | 2008-10-23 | 2009-03-25 | 侯召亮 | Medicine for treating hyperosteogeny |
| CN101700395A (en) * | 2009-11-24 | 2010-05-05 | 张套林 | Ointment for curing hyperosteogeny |
-
2013
- 2013-12-18 CN CN201310698948.4A patent/CN103656001A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101390988A (en) * | 2008-10-23 | 2009-03-25 | 侯召亮 | Medicine for treating hyperosteogeny |
| CN101700395A (en) * | 2009-11-24 | 2010-05-05 | 张套林 | Ointment for curing hyperosteogeny |
Non-Patent Citations (2)
| Title |
|---|
| 凌伟等: "骨质增生症中药外治概况", 《中医药信息》 * |
| 邹波: "中药外贴内服治疗腰椎骨质增生260例", 《中医外治杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288015A (en) * | 2015-12-03 | 2016-02-03 | 乔永平 | Combined crude drug ointment for treating hyperostosis |
| CN105327328A (en) * | 2015-12-12 | 2016-02-17 | 林炜 | Formula for treating osteoproliferation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102266541B (en) | Chinese medicinal plaster for treating hyperosteogeny or hyperosteogeny pain | |
| CN101890104B (en) | Chinese medicament for treating neck, shoulder, waist and leg pains | |
| CN103156972B (en) | Traditional Chinese medicine combination for treating fracture, hairline fracture and traumatic injury | |
| CN103599494A (en) | Externally applied traditional Chinese medicine for treatment of cervical spondylosis | |
| CN103784769A (en) | Chinese herbal preparation for treating orthopedic diseases | |
| CN103463241A (en) | Traditional Chinese medicine composition for treating lumbar disc herniation | |
| CN103751306A (en) | Anti-rheumatic, anti-inflammatory and antalgic pharmaceutical composition | |
| CN102526406B (en) | Traditional Chinese medicine plaster for treating cervical spondylotic radiculopathy and preparation method thereof | |
| CN106266939A (en) | A kind of Chinese medicine composition, the transdermal patch for neck waist rehabilitation comprising this Chinese medicine composition and preparation and application | |
| CN103768175A (en) | Medicine for treating protrusion of lumbar intervertebral disc and drug-separated moxibustion of medicine | |
| CN103463580B (en) | Chinese medicine ointment for treating pain of muscles, bones and joints and preparation method thereof | |
| CN102961483B (en) | Traditional Chinese medicine composition for treating pain in waist and lower extremities and preparation method thereof | |
| CN102949680B (en) | Medicinal liquor for treating cervical spondylosis and preparation method thereof | |
| CN106177819A (en) | A kind of external medicine composition for cervical spondylosis, preparation method and applications | |
| CN103656001A (en) | Compound medicine for treating osteoproliferation | |
| CN104940591A (en) | Plaster for treating lumbar disc herniation | |
| CN104208635A (en) | Externally used traditional Chinese medicine composition for relieving pain and preparation method thereof | |
| CN102949507B (en) | Traditional Chinese medicine lotion for treating lumbocrural pain and preparation method thereof | |
| CN105497824A (en) | Traditional Chinese medicine composition for treating calcaneodynia | |
| CN105288481A (en) | Chinese medicinal composition for treating arthromyodynia and relieving pain and preparation method of paste thereof | |
| CN104491828A (en) | Warming pain relief Chinese materia medica preparation and paste preparing method thereof | |
| CN105194001A (en) | Anti-swelling and pain-killing ointment and preparation method thereof | |
| CN104940863A (en) | Medical dressing paste for treating sciatica | |
| CN104758527A (en) | Traditional Chinese medicine composition for treating pain in waists and legs | |
| CN103961618A (en) | Plaster for treating pains caused by wind-cold damp pathogens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140326 |